Short Communication

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database

Benjamin W. Fischer-Valuck\textsuperscript{a,b}, Jeff M. Michalski\textsuperscript{a}, Jessika A. Contreras\textsuperscript{a}, Randall Brenner\textsuperscript{a}, John P. Christodoulou\textsuperscript{c}, Christopher D. Abraham\textsuperscript{d}, Eric H. Kim\textsuperscript{d}, Vivek K. Arora\textsuperscript{e}, Arnold D. Bullock\textsuperscript{d}, Ruben Carmona\textsuperscript{c}, Robert S. Figenshau\textsuperscript{d}, Robert Grubb\textsuperscript{III}\textsuperscript{d}, Eric M. Knoche\textsuperscript{e}, Russell K. Pachynski\textsuperscript{e}, Joel Picus\textsuperscript{e}, Bruce J. Roth\textsuperscript{e}, Paul Sargos\textsuperscript{f}, Gerald L. Andriel\textsuperscript{d}, Hiram A. Gay\textsuperscript{a}, Brian C. Baumann\textsuperscript{a,*}

\textsuperscript{a}Washington University in St. Louis, Department of Radiation Oncology, St. Louis, MO, United States
\textsuperscript{b}Emory University, Winship Cancer Institute, Department of Radiation Oncology, Atlanta, GA, United States
\textsuperscript{c}University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA, United States
\textsuperscript{d}Washington University in St. Louis, Division of Urology, St. Louis, MO, United States
\textsuperscript{e}Washington University in St. Louis, Division of Medical Oncology, St. Louis, MO, United States
\textsuperscript{f}Département de radiothérapie, Institut Bergonié, Bordeaux, France

\textbf{Introduction:} Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT.

\textbf{Materials/methods:} We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses.

\textbf{Results:} 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and Charlson-Deyo comorbidity index [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001]. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013).

\textbf{Conclusions:} This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted.

\textcopyright{} 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Squamous cell carcinoma (SqCC) of the bladder is the second most common histologic variant of bladder cancer [1,2]. Most blad-
nder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). There is limited data on the efficacy of these treatments in SqCC, particularly for definitive chemoradiotherapy (CRT). In this study, we performed a propensity analysis to compare overall survival outcomes between SqCC and UC patients treated with definitive CRT.

2. Materials/methods

2.1. Data source and study population

Using the National Cancer Database (NCDB), we identified patients with clinical T2-4N0M0 bladder cancer diagnosed between 2004 and 2013 with complete demographic and treatment information [3]. All patients underwent transurethral resection of bladder tumor (TURBT) prior to definitive concurrent CRT. Patients who underwent cystectomy were excluded. Only patients receiving radiation therapy to the bladder or pelvis and total dose ≥40 Gy were included.

2.2. Statistical analysis

Overall survival (OS) was calculated from diagnosis until death, censoring at last follow-up for patients who were alive. The Kaplan-Meier method was used to estimate OS probabilities and Cox univariable and multivariable analyses were performed on all patients. The χ² test and Fisher’s exact test were used to evaluate contingency tables, as appropriate. Variables with p-values <0.05 on univariable testing were entered into a multivariable analyses using the Cox proportional-hazards model. Propensity score analysis was performed to correct for baseline differences between histologic groups. A 1:1 matching algorithm including the variables used in univariable analysis was used with a caliper of 0.2 and without replacement. Significance was considered at a value of p < 0.05. SPSS v24 (IBM; Armonk, NY) was used.

3. Results

3.1. Demographics, patient and tumor characteristics

3332 CRT patients were identified with a median follow-up of 24.0 months (range, 1–142 months). 79 (2.3%) patients had SqCC and the remaining 3253 (97.7%) patients were diagnosed with UC. The median age was 78 years (range, 37–90) for SqCC patients and 77 years (range, 24–90) for UC patients. Patient demographic and clinical characteristics are summarized in Table 1. The majority of SqCC patients (54.4%) were female compared to 26.1% of patients with UC. 73.4% of SqCC patients had clinical T2 disease compared to 29.5% for UC, respectively (P < 0.0001). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1). The estimated 3- and 5-year OS for SqCC were 27.5% and 29.4 months (95% CI, 27.8–31.1) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1).

3.2. Outcomes

The median OS of the entire cohort was 29.0 months (95% confidence interval [CI], 27.4–30.6 months). Patients with clinical T2 disease had median OS of 31.1 months (95% CI, 29.1–33.0) compared to 20.1 (95% CI, 17.8–23.6) and 20.7 (95% CI, 17.7–23.7) months for clinical T3 and T4 stage, respectively (P < 0.001 T2 versus T3 and T4). The unadjusted median overall survival for patients with SqCC was 15.6 months (95% CI, 11.7–19.6) versus 29.4 months (95% CI, 27.8–31.1) for those with UC (P < 0.0001) (Fig. 1).

3.3. Univariable and multivariable analyses

On univariable analysis OS was affected by age, Charlson-Deyo comorbidity index (CCI), histology (UC versus SqCC), and clinical T-stage (Table 2). In the multivariable model, SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and CCI [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001] were associated with worse OS.

3.4. Matched cohort

Propensity score matching between the SqCC and UC histology groups was performed to address confounding patient, tumor, and demographic bias between the groups. This resulted in a successful
match of 77 pairs of patients between SqCC and UC (154 total patients). There were no significant imbalances in matched variables in the resulting cohort and propensity scores were well matched (all standardized mean differences <0.2). For the matched cohort, the median OS for SqCC patients was 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC after propensity match adjusted analysis (P = 0.013, Fig. 2).

**4. Discussion**

Despite an overall increase in the incidence of bladder cancer in the USA over the last 40 years, the incidence of SqCC has declined but overall survival after therapy remains poor [1,4]. An NCDB analysis demonstrated that patients with SqCC are more likely to be diagnosed with advanced disease than UC patients [1]. In a study from MD Anderson, SqCC patients were more likely to present with locally advanced disease and were more likely to fail loco-regionally [2]. Achieving local control for SqCC is therefore of particular importance, given the pattern of failure for SqCC and the morbidity and mortality of local recurrence [5–7]. The treatment strategies for localized SqCC are largely extrapolated from the treatment of urothelial bladder cancer and often include radiation therapy, radical cystectomy, and definitive CRT [4].

Several studies have reported worse survival outcomes for SqCC treated with either radical cystectomy or definitive RT alone compared to similarly treated patients with UC [8–13], but there

**Table 2 Univariate and multivariate analysis.**

| Variable              | Univariate Analysis | Multivariate Analysis |
|-----------------------|---------------------|-----------------------|
|                       | HR (95% CI)         | P-value               | HR (95% CI)         | P-value               |
| **Histology**         |                     |                       |                      |                       |
| UC                    | Reference group     | 1.60 (1.24–2.05)      | <0.0001              | Reference group       | 1.51 (1.17–1.94)      | 0.001               |
| SCC                   |                      |                        |                       |                        |                       |                     |
| **Age (y)**           |                     |                       |                       |                       |                       |                     |
| <75                   | Reference group     | 1.46 (1.34–1.59)      | <0.0001              | Reference group       | 1.47 (1.35–1.60)      | <0.0001             |
| >75                   |                      |                        |                       |                        |                       |                     |
| **Sex**               |                     |                       |                       |                       |                       |                     |
| Male                  | Reference group     | 1.09 (0.99–1.19)      | 0.084                | –                     | –                     | –                   |
| Female                |                      |                        |                       |                       |                       |                     |
| **Race**              |                     |                       |                       |                       |                       |                     |
| White                 | Reference group     | 1.00 (0.99–1.00)      | 0.259                | –                     | –                     | –                   |
| Nonwhite              |                      |                        |                       |                       |                       |                     |
| **Year of Diagnosis** |                     |                       |                       |                       |                       |                     |
| 2004–2009             | Reference group     | 1.024 (0.94–1.12)     | 0.598                | –                     | –                     | –                   |
| 2010–2013             |                      |                        |                       |                       |                       |                     |
| **CCI**               |                     |                       |                       |                       |                       |                     |
| 0                     | Reference group     | 1.16 (1.05–1.28)      | 0.003                | Reference group       | 1.17 (1.06–1.29)      | 0.002               |
| 1                     |                      |                        |                       |                        |                       |                     |
| >1                    | Reference group     | 1.66 (1.48–1.92)      | <0.0001              | Reference group       | 1.64 (1.44–1.87)      | <0.0001             |
| **Program Type**      |                     |                       |                       |                       |                       |                     |
| Academic/Research Program | Reference group   | –                     | –                     | –                     | –                     | –                   |
| Other                 | 1.01 (1.0–1.0)      | 0.246                | –                     | –                     | –                     | –                   |
| **Clinical T stage**  |                     |                       |                       |                       |                       |                     |
| T2                    | Reference group     | 1.46 (1.28–1.66)      | <0.0001              | Reference group       | 1.41 (1.24–1.61)      | <0.0001             |
| T3                    |                      |                        |                       |                        |                       |                     |
| T4                    | 1.36 (1.17–1.58)    | <0.0001              |                       | 1.36 (1.17–1.58)      | <0.0001              |                     |

Bold = statistically significant (P < 0.05).
is limited data on SqCC patients treated with CRT. In one of the larger surgical series, Ehdai et al. found that pure SCC (n = 78) was associated with significantly worse OS and disease-specific survival compared to UC for patients treated with radical cystectomy [13]. In a study of SqCC patients treated with definitive RT alone from the early 1980s, Prempree et al. reported a 3-year disease-free survival of ~16% for 33 SqCC patients treated to 60–65 Gy, results that compare unfavorably to contemporary series of RT alone for UC [11]. Given the unfavorable outcomes with radiation alone in SqCC and the results of randomized controlled trials in UC demonstrating improved survival with CRT vs. RT alone [14,15], it seems reasonable to combine radiation therapy with chemotherapy for SqCC patients to take advantage of chemotherapy's radiosensitizing effects, even though chemotherapy appears to have less benefit for SqCC than UC [16–18]. The BC2001 trial of CRT with 5-FU and mitomycin C vs. RT did allow SqCC patients on study, but only 2.7% (8 patients) had SqCC or adenosquamous carcinoma [15]. Given the effectiveness and tolerability of 5-FU and mitomycin C in SqCC of the anus, the use of this regimen in SqCC of the bladder appears reasonable, especially for patients who are platinum-ineligible. Our purpose in this study was to determine the overall survival of SqCC patients treated with CRT and compare overall survival outcomes between SqCC and UC patients.

In our study, we found that SqCC patients treated with CRT had worse overall survival compared to UC patients in a multivariable model. The discrepancy in overall survival remained after propensity score matching between SqCC and UC. In light of the poor outcomes with definitive CRT in SqCC patients compared to UC patients, treatment intensification strategies for SqCC may be warranted, such as the use of immunotherapy, novel chemotherapeutic strategies, or radiation dose escalation/hypofractionation. Additionally, our findings are not a comparison of CRT versus radical cystectomy for this uncommon histology. Ehdai et al. reported an estimated 5-year OS of 40% (95% CI, 28–51) for SqCC which is superior to the survival in our study, however many patients receiving CRT may have been inoperable due to comorbidities or other various reasons [13]. This comparison, however, suggests a role for radical cystectomy in surgical candidates. Institutional retrospective and future prospective studies comparing CRT and radical cystectomy are encouraged.

There are several limitations to this retrospective analysis. In our study, the OS for patients with UC treated with CRT was worse than the OS reported in prior RCTs and large single-institution retrospective series. For example, the BC2001 trial reported a five-year OS of 48% compared to only 30% in our study [15]. This difference may be related to the older median age in our cohort and inclusion of patients with co-morbidities who would have been excluded from a RCT as well as heterogeneity in the radiation dose, treatment volumes, and chemotherapy administration. Importantly, the lack of details on chemotherapeutic regimens used in this study (e.g. chemotherapy agent(s), number of cycles administered, and dose reductions) is a major limitation of the database. Another limitation of this study is that while the size of the UC cohort treated with CRT is large, the size of the SqCC cohort is relatively small. Lastly, limitations include those inherent to the NCDB, such as the potential for unidentified confounding factors and missing/miscoded data.

5. Conclusions

This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this observational study, SqCC had worse overall survival compared to UC patients. On propensity analysis, OS remained significantly worse for the SqCC cohort. While the sample size is relatively small and subject to selection bias, the results suggest that treatment intensification strategies may be reasonable for this less common histologic subtype.

Funding sources

None.

Conflict of interest

John P. Christodoulueas reports employee status at Elekta, Inc.

References

[1] Royce TJ, Lin CC, Gray PJ, Shipley WJ, Jemal A, Efstathiou JA. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base. Urol Oncol 2018;36(2):78.e1–78.e12.
[2] Kassouf W, Spiess PE, Sieffer-Radzie A, et al. Outcome and patterns of recurrence of non-bilaterial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 2007;110(4):764–9.
[3] Fischer-Valuck BW, Rao YJ, Rudra S, et al. Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the national cancer database. J Urol 2018;199(2):416–23.
[4] Abdel-Rahman O. Squamous cell carcinoma of the bladder: a SEER database analysis. Clin Genitourinary Cancer 2017;15(3):e463–8.
[5] Baumann BC, Sargos P, Eapen LJ, et al. The rationale for post-operative radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2002;20(2_suppl). abstract 356-356.
[6] None.

Conflict of interest

John P. Christodoulueas reports employee status at Elekta, Inc.

References

[1] Royce TJ, Lin CC, Gray PJ, Shipley WJ, Jemal A, Efstathiou JA. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base. Urol Oncol 2018;36(2):78.e1–78.e12.
[2] Kassouf W, Spiess PE, Sieffer-Radzie A, et al. Outcome and patterns of recurrence of non-bilaterial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 2007;110(4):764–9.
[3] Fischer-Valuck BW, Rao YJ, Rudra S, et al. Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the national cancer database. J Urol 2018;199(2):416–23.
[4] Abdel-Rahman O. Squamous cell carcinoma of the bladder: a SEER database analysis. Clin Genitourinary Cancer 2017;15(3):e463–8.
[5] Baumann BC, Sargos P, Eapen LJ, et al. The rationale for post-operative radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2002;20(2_suppl). abstract 356-356.